Davidf Hale News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Davidf hale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Davidf Hale Today - Breaking & Trending Today
Research analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock. A number of other research analysts have also recently weighed in on the stock. HC Wainwright cut shares of Oncternal […] ....
StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research note published on Tuesday morning. The brokerage issued a sell rating on the stock. A number of other analysts also recently issued reports on ONCT. HC Wainwright downgraded shares of Oncternal Therapeutics from a buy rating to a neutral rating […] ....
StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research report sent to investors on Tuesday morning. The firm issued a sell rating on the stock. A number of other brokerages also recently weighed in on ONCT. Oppenheimer downgraded Oncternal Therapeutics from an outperform rating to a market perform rating […] ....
StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a report published on Monday. The firm issued a sell rating on the stock. A number of other brokerages have also recently issued reports on ONCT. Oppenheimer cut shares of Oncternal Therapeutics from an outperform rating to a market perform rating in […] ....
Research analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a report released on Monday. The firm set a “sell” rating on the stock. ONCT has been the subject of several other reports. Brookline Capital Acquisition reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a research report […] ....